Mineralys Therapeutics, Inc./$MLYS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Ticker
$MLYS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
51
ISIN
US6031701013
Website
MLYS Metrics
BasicAdvanced
$895M
-
-$3.73
-0.18
-
Price and volume
Market cap
$895M
Beta
-0.18
52-week high
$18.38
52-week low
$8.69
Average daily volume
795K
Financial strength
Current ratio
26.483
Quick ratio
25.626
Profitability
EBITDA (TTM)
-201.438
Management effectiveness
Return on assets (TTM)
-35.87%
Return on equity (TTM)
-56.31%
Valuation
Price to book
2.61
Price to tangible book (TTM)
2.61
Price to free cash flow (TTM)
-3.606
Free cash flow yield (TTM)
-27.73%
Free cash flow per share (TTM)
-380.79%
Growth
Earnings per share change (TTM)
69.12%
Bulls say / Bears say
HC Wainwright reissued a 'buy' rating for Mineralys Therapeutics with a $30.00 target price, suggesting a potential upside of approximately 193% from the current price. (americanbankingnews.com)
Mineralys Therapeutics has completed enrollment in two pivotal trials for lorundrostat targeting uncontrolled and resistant hypertension, with topline data expected in March 2025 and mid-first half 2025, respectively. (biospace.com)
The company reported cash, cash equivalents, and investments totaling $198.2 million as of December 31, 2024, believed to be sufficient to fund planned clinical studies and operations through the first quarter of 2026. (defenseworld.net)
Mineralys Therapeutics reported a net loss of $177.8 million for the year ended December 31, 2024, compared to $71.9 million for 2023, primarily due to increased R&D and G&A expenses. (defenseworld.net)
Insider trading activity shows that company executives have sold shares in recent months, which can be perceived negatively by investors. (nasdaq.com)
The company has no long-term liabilities, but its cash runway is forecasted to last for only nine months based on free cash flow estimates, indicating potential future financing needs. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
MLYS News
AllArticlesVideos
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
GlobeNewsWire·4 weeks ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
GlobeNewsWire·1 month ago
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mineralys Therapeutics, Inc. stock?
Mineralys Therapeutics, Inc. (MLYS) has a market cap of $895M as of June 20, 2025.
What is the P/E ratio for Mineralys Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Mineralys Therapeutics, Inc. (MLYS) stock is 0 as of June 20, 2025.
Does Mineralys Therapeutics, Inc. stock pay dividends?
No, Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Mineralys Therapeutics, Inc. dividend payment date?
Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders.
What is the beta indicator for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. (MLYS) has a beta rating of -0.18. This means that it has an inverse relation to market volatility.